Keyword: Intercept Pharmaceuticals

Novartis headquarters

Novartis | Tropifexor and licogliflozin

Novartis has two NASH prospects in phase 2. The first, tropifexor, is one of a crowd of FXR agonists, and the second, licogliflozin, is an SGLT1/2 inhibitor, which works by blocking the absorption and reabsorption of glucose—a mechanism familiar to diabetes that could make a dent in NASH.

Genfit | Elafibranor

Although Intercept’s OCA is on track to beat elafibranor to market, Genfit is hopeful its candidate could be better. For starters, it has a different mechanism: Elafibranor is a dual agonist of PPAR-alpha and PPAR-delta, a type of protein found inside cells that plays a role in cellular metabolism.

Intercept Pharmaceuticals | Obeticholic acid (OCA)

Intercept already sells obeticholic acid as Ocaliva for the treatment of primary biliary cholangitis; it earned the FDA nod for that liver disease back in 2016. Intercept submitted OCA for FDA approval in NASH in September and plans to follow up with a European Medicines Agency filing by the end of the year.